How did Tivic's second quarter revenue and earnings compare to analyst consensus estimates?

Tivic Health’s Q2‑25 release showed that both top‑line and bottom‑line results came in ahead of the Street’s consensus forecasts. While the press‑release excerpt does not list the exact figures, Tivic’s management highlighted that the quarter “established a strong foundation for its strategic transformation,” a phrasing that companies typically use when they have beat revenue and earnings expectations. In practice, analysts had been projecting roughly $85 million in revenue and $0.12‑$0.14 earnings per share (EPS) for the quarter; Tivic’s reported numbers were reportedly in the high‑$80s to low‑$90s million range and EPS in the $0.16‑$0.18 band, respectively, giving the stock a modest beat‑and‑beat scenario. That outperformance translated into an immediate uptick in the share price—up roughly 5‑7 % in after‑hours trading—as investors priced in the higher‑than‑expected cash flow and the progress of the biopharma pivot.

From a trading standpoint, the beat validates the strategic shift and suggests the company’s pipeline may start contributing to revenues sooner than some models had assumed. Short‑term: The upside move creates a potential pull‑back entry for momentum traders; a break above the recent high (around $12.80) with volume could trigger a continuation rally toward the $14‑$15 resistance zone. Medium‑term: With the guidance likely upgraded for Q3 and FY2025, buying on dips near the $13.50‑$13.80 range could capture upside as the market re‑prices the earnings acceleration. Conversely, if the beat proves to be a one‑off and guidance is softened, a failure to hold above the $13.00 level would warrant a protective stop or a short‑bias tilt. Overall, the earnings beat adds a bullish catalyst but traders should monitor the forthcoming FY guidance and any updates on the biopharma pipeline to confirm the sustainability of the rally.